



Proposals of the Nomination Committee for the Annual General Meeting of Acarix AB (publ) on June 17, 2026

The Nomination Committee of Acarix AB (publ), corporate ID no. 559009-0667 ("the Company"), consisting of Jan Poulsen (Chairman), Mikael Thorén, and Jake Nossaman, submits the following proposals regarding the Board of Directors and Board remuneration for the Annual General Meeting on June 17, 2026. The full notice of the meeting is available on the Company's website at www.acarix.com.

Chair of the Annual General Meeting (Item 1 of the Notice)

The Nomination Committee proposes that attorney Mattias Prage of the law firm Lindahl be appointed as Chair of the meeting.

Proposal regarding the number of Board members (item 9 of the notice)

The Nomination Committee proposes that the Board of Directors consist of five (5) ordinary members without alternates. The addition of one member compared to the previous year is due to the fact that the Chairman of the Board, Jan Poulsen, plans to leave the Board due to time constraints. Jan Poulsen has agreed to remain as Chairman during a transition period—at the latest until the 2027 Annual General Meeting—to ensure a smooth introduction of the new members.

Proposed remuneration for Board members and the auditor (item 10 in the notice of meeting)

The Nomination Committee proposes that Board remuneration be paid in the amount of SEK 500,000 to the Chairman of the Board and SEK 300,000 to each of the other Board members. It is further proposed that no remuneration be paid for work on committees. Remuneration to the auditor is proposed to be paid in accordance with an approved invoice. The proposal regarding remuneration is unchanged from the previous Annual General Meeting.

The Board of Directors proposes that the Annual General Meeting resolve to establish a Nomination Committee in accordance with the provisions below. The Nomination Committee's instructions shall remain in effect until the Annual General Meeting adopts new ones.

Proposal for the Board of Directors and Chairman of the Board (Item 11 in the Notice)

The Nomination Committee proposes the re-election of Jan Poulsen, Ken Nelson, and Dr. Tony Das as ordinary members of the Board of Directors. Marlou Janssen-Counott has declined re-election due to other commitments. The Nomination Committee proposes the election of Erik von Schenck and Marcin Gołębicki as new ordinary members of the Board of Directors. All members are elected for a term of office until the end of the next Annual General Meeting. Jan Poulsen is proposed for re-election as Chairman of the Board. A brief



presentation of the proposed new Board members follows below.

Erik von Schenck

Erik von Schenck is an experienced MedTech leader with more than 35 years of global experience in product innovation, market development, and corporate governance. He served as Vice President of Global R&D at Stryker Emergency Care from 2018 to 2026, overseeing global product development for LUCAS, LIFEPAK, and LIFENET, among others, during which time the business unit grew organically from \$750 million to \$2 billion in revenue. Prior to that, he served as CEO of Jolife AB (2004–2011), where he led the LUCAS mechanical CPR system from startup to global market leader and executed a successful sale to Physio-Control. He was also CEO of Jostra AB (2001–2004), where he was responsible for the heart-lung machine business, which was divested to Getinge, and previously held leadership roles at Gambro AB. Erik von Schenck is currently Chairman of the Board at Avidicare AB and BiBB Instruments AB. He holds a Master of Science in Mechanical Engineering and an Executive MBA, both from Lund University. To the best of the Nomination Committee's knowledge, Erik von Schenck currently owns no shares in Acarix AB.

Marcin Gołębicki

Marcin Gołębicki is an international MedTech leader with more than 25 years of experience in P&L responsibility and business development across more than 40 countries. He is the founder and CEO of Renavie Sensing (since 2026), a company developing non-invasive diagnostic solutions for the treatment of hypertension. Prior to that, he was CEO and a board member of EP Solutions SA in Switzerland (2022–2026), whose technology was named Best New Cardio Technology by HRS/Stanford Biodesign in 2023, and which was successfully divested under his leadership. He has also served as Acting CEO of Medicalgorithmics (2019–2021) and VP EMEA & International Markets at Philips EPD Solutions (2019–2021). From 2010 to 2018, he was VP CEEMEA & Asia at Abbott/St. Jude Medical, responsible for 40 countries and a P&L of more than \$380 million, and led Abbott's post-merger integration of St. Jude Medical in EMEA and Asia. Prior to that, he was Senior Managing Director for CEE, Russia, and Central Asia at Boston Scientific (2006–2010). He began his career at Johnson & Johnson and was one of the youngest individuals ever appointed to the company's global Worldwide Management Board. Marcin Gołębicki holds an MBA from Harvard University (Advanced Management Program) and an MBA from the University of Minnesota. To the best of the Nomination Committee's knowledge, Marcin Gołębicki currently owns no shares in Acarix AB.

Proposal for Auditor (Item 12 in the Notice)

The Nomination Committee proposes the re-election of the current auditor, Öhrlings PricewaterhouseCoopers, with Alexander Ståhl as the principal auditor.

Proposal for instructions to the Nomination Committee (item 13 in the notice)



The Meeting instructs the Chairman of the Board to contact the three largest shareholders in terms of voting rights, as per Euroclear's printout of the share register as of September 30 of each year, each of whom shall appoint one member of the Nomination Committee. In the event that any of the three largest shareholders does not wish to appoint a member of the Nomination Committee, the fourth-largest shareholder shall be asked (and so on) until the Nomination Committee consists of three members.

The members of the Nomination Committee shall be announced on the Company's website no later than six months prior to the next Annual General Meeting. The website shall also include information on how shareholders may submit proposals to the Nomination Committee.

The Nomination Committee shall appoint a chairperson from among its members. However, the Chairman of the Board or any other Board member may not serve as chairperson of the Nomination Committee. Board members may serve on the Nomination Committee, but may not constitute a majority of its members. The CEO or any other member of management may not serve as a member of the Nomination Committee. The majority of the Nomination Committee's members shall be independent of the Company and the Company's management. At least one of the Nomination Committee's members shall also be independent of the Company's largest shareholder in terms of voting rights, or any group of shareholders acting in concert with respect to the governance of the Company.

If a member leaves the Nomination Committee before its work is completed and the Nomination Committee deems it necessary to replace that member, the Nomination Committee shall appoint a new member in accordance with the principles above, but based on the ownership structure in effect at that time. Any change in the composition of the Nomination Committee shall be announced.

No remuneration shall be paid to the members of the Nomination Committee for their work.

Prior to the Annual General Meeting, the Nomination Committee shall submit proposals for resolutions on the following matters:

- a) Chair of the meeting.
- b) Number of Board members.
- c) Fees and other compensation paid to the Board, broken down between the Chairman and other members.
- d) Fees paid to the auditor.
- e) Election of Board members and the Chairman of the Board.
- f) Election of the auditor.



g) New instructions for the Nomination Committee (if applicable).

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 60,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). The Company's Certified Adviser is Tapper Partners AB. For more information, please visit www.acarix.com

For more information, contact

Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments

[Proposals of the Nomination Committee for the Annual General Meeting of Acarix AB \(publ\) on June 17, 2026](#)